ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.75
-0.92%
US Tech 100
18,837.60
-1.25%
S&P 500
5,521.52
-1.39%
US Dollar vs CAD
1.44312
0.02%
Bitcoin
81,972.75
1.15%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Oncocyte Corporation (OCX)

  7. Oncocyte Corporation (OCX) News

OCX

Oncocyte (OCX)

Oncocyte Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCX
DateTimeSourceHeadlineSymbolCompany
03/10/20253:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
02/24/20255:03AMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OCXOncocyte Corporation
02/11/20256:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
02/11/20257:30AMGlobeNewswire Inc.Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNASDAQ:OCXOncocyte Corporation
02/10/20258:17AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
02/10/20258:03AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCXOncocyte Corporation
02/10/20257:30AMGlobeNewswire Inc.Oncocyte Prices $29.1 Million Equity OfferingNASDAQ:OCXOncocyte Corporation
01/08/20253:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
01/08/20257:30AMGlobeNewswire Inc.Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerNASDAQ:OCXOncocyte Corporation
01/06/20253:05PMGlobeNewswire Inc.Oncocyte Expands Market Opportunity for VitaGraft™ KidneyNASDAQ:OCXOncocyte Corporation
12/09/20243:05PMGlobeNewswire Inc.Oncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsNASDAQ:OCXOncocyte Corporation
12/09/20247:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
12/04/20243:15PMGlobeNewswire Inc.Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyNASDAQ:OCXOncocyte Corporation
12/02/20243:05PMGlobeNewswire Inc.Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms NASDAQ:OCXOncocyte Corporation
11/12/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCXOncocyte Corporation
11/12/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
11/12/20243:05PMGlobeNewswire Inc.Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025NASDAQ:OCXOncocyte Corporation
11/06/20243:45PMGlobeNewswire Inc.Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12NASDAQ:OCXOncocyte Corporation
10/22/20243:12PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCXOncocyte Corporation
10/21/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
10/18/20243:55PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:OCXOncocyte Corporation
10/16/20244:16PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCXOncocyte Corporation
10/16/20243:15PMGlobeNewswire Inc.Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesNASDAQ:OCXOncocyte Corporation
10/15/20243:22PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
10/15/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
10/08/20243:05PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OCXOncocyte Corporation
10/08/20247:30AMGlobeNewswire Inc.Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialNASDAQ:OCXOncocyte Corporation
10/04/20246:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
10/03/20245:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
10/02/20245:41PMGlobeNewswire Inc.Oncocyte Signs Leading Transplant Centers in US and GermanyNASDAQ:OCXOncocyte Corporation
 Showing the most relevant articles for your search:NASDAQ:OCX

Your Recent History

CSE
VGC.H
Happy Supplements
GDAX
SUKUEUR
SUKU
BIT
P1JHU5
BNP Paribas Issuance
LSE
42XL
Inter 2042
DOWI
DWCIDM
DJ US Industrial Metals ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads